in the absence of a submission from the holder of the marketing authorisation:
tenofovir alafenamide (Vemlidy®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice58KB (PDF)
- Medicine name:
- tenofovir alafenamide (Vemlidy)
- SMC ID:
- Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 10 April 2017